The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, Tukysa and Tivdak — to the company’s portfolio. In first-quarter 2025, oncology contributed more than 25% to Pfizer’s ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Pfizer PFE will report its second-quarter 2025 earnings on Aug. 5, before market open. The Zacks Consensus Estimate for sales ...

Pfizer said it still expects adjusted 2025 profit of $2.80 a share to $3 a share, while analysts expect full-year earnings of $2.94 a share.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

The goal is to make drug prices more in line with European ones. If this were the case, it could result in a massive 24% hit on all firms’ US drug revenue, detrimental to Pfizer.

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its ...